Azevan Pharmaceuticals Inc

Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing V1a antagonists to address a large unmet need in traumatic brain injury and related CNS disorders. Over 55 million TBI cases occur each year, with the large majority classified as mild, yet care remains largely supportive and no approved drugs improve neurological outcomes. The company's V1a antagonists interrupt the AVP-driven secondary injury cascade upstream of edema, with pipeline programs spanning neurodevelopmental, neurodegenerative, and acute indications.